Neurofilament in clinical practice: Is the multiple sclerosis community ready?
Multiple Sclerosis Journal · 2024
DOI: 10.1177/13524585241246536 ↗Kurz gefasst
Editorial in der Zeitschrift Multiple Sclerosis Journal, 2024. Verfasst von Marcello Moccia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Multiple Sclerosis, Neurofilament Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Neurofilament light chain (NfL) is a component of the cytoskeleton of the neuron, that is released in the presence of neuro-axonal injury.1,2 NfL can be measured in the peripheral blood using ultrasensitive laboratory methods, and has been used as a marker of inflammatory and degenerative aspects of multiple sclerosis (MS) in research studies.1,2 The Consortium of MS Centers (CMSC) has just released their consensus best practices for the use of serum NfL in the clinical management of people with MS, from diagnosis to follow-up.3 Elevated NfL in the peripheral blood has been demonstrated from the time of clinical onset of MS, with potential implications for diagnosis.4 In the context of local healthcare services less confident on definitions of typical clinical and/or radiological presentations of MS, NfL in the peripheral blood might serve to quickly screen and grant referral to neurology specialist and further investigations.Also, elevated NfL has been shown in the stages preceding clinical presentation and diagnosis of MS, 5 and, thus, could allow early identification of MS pathobiologies in at-risk individuals with no or non-specific symptoms (e.g.fatigue and depression).6 However, NfL lacks of diagnostic specificity, being elevated from the early stages of many (if not all) neurological diseases, 4 and, on the current ground, there is no supporting data for its inclusion in the next set of diagnostic criteria.Besides, normal or low NfL at the time of clinical and/or radiological presentations should raise concerns over the diagnosis of MS, and could be used to increase the specificity of MS diagnosis, as needed.[7][8][9]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
- Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Naples, Italy.
- Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
- Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples Federico II, Naples, Italy.
- Centre for Advanced Biotechnology (CEINGE), Naples, Italy.
ORCID-Profile: Marcello Moccia
Zitieren
APA
Moccia, M., Terracciano, D., Brescia Morra, V., & Castaldo, G. (2024). Neurofilament in clinical practice: Is the multiple sclerosis community ready?. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585241246536
Vancouver
Moccia M, Terracciano D, Brescia Morra V, Castaldo G. Neurofilament in clinical practice: Is the multiple sclerosis community ready?. Multiple Sclerosis Journal. 2024. doi:10.1177/13524585241246536
BibTeX
@article{Moccia2024,
author = {Moccia, Marcello and Terracciano, Daniela and Brescia Morra, Vincenzo and Castaldo, Giuseppe},
title = {Neurofilament in clinical practice: Is the multiple sclerosis community ready?},
journal = {Multiple Sclerosis Journal},
year = {2024},
doi = {10.1177/13524585241246536}
}
EUVIMED